Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH

Transplantation

Volumn 86, Issue 3, 2008, Pages 460-468

  Haeryfar, S M Mansour ^a,b   Lan, Zhu ^a   Leon Ponte, Matilde ^a   Duffy, Kathleen Rose Langley ^a   Ge, Wei ^a   Liu, Weihua ^a   Mele, Tina ^a   Garcia, Bertha ^a   Wang, Hao ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Heart transplantation; Immunotherapy; Invariant natural killer T cells; Rapamycin

Indexed keywords

ALLOANTIBODY; ALPHA GALACTOSYLCERAMIDE OCH; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; GLYCOLIPID; IMMUNOSUPPRESSIVE AGENT; TETRACOSANOIC ACID 1 GALACTOPYRANOSYLOXY 3,4 DIHYDROXYDEC 2 YL AMIDE; TETRACOSANOIC ACID 1-GALACTOPYRANOSYLOXY-3,4-DIHYDROXYDEC-2-YL AMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIAC GRAFT REJECTION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EXPERIMENTAL MODEL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; HLA MATCHING; IMMUNOTHERAPY; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C3H MOUSE; C57BL MOUSE; DRUG COMBINATION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; NATURAL KILLER CELL; PATHOLOGY; T LYMPHOCYTE RECEPTOR GENE; TH2 CELL; TIME;

ANIMALS; CYTOKINES; DRUG THERAPY, COMBINATION; GENES, T-CELL RECEPTOR ALPHA; GLYCOLIPIDS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; RNA, MESSENGER; SIROLIMUS; TH2 CELLS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 52049094907     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181806b72     Document Type: Article

References (39)

1. Wang H, Hosiawa KA, Min W, et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol 2003; 171: 3823.
2. Hutchinson IV, Turner DM, Sankaran D, et al. Influence of cytokine genotypes on allograft rejection. Transplant Proc 1998; 30: 862.
3. McDaniel DO, Barber WH, Nguyan C, et al. Combined analysis of cytokine genotype polymorphism and the level of expression with al-lograft function in African-American renal transplant patients. Transpl Immunol 2003; 11: 107.
4. Lessan-Pezeshki M, Amirzargar A, Fathi A, et al. Value of pretransplantation cytokine profiles for predicting acute rejection in renal transplant recipients. Transplant Proc 2005; 37: 2982.
5. Bromberg JS, MurphyB. Routes to allograft survival. J Clin Invest 2001; 107: 797.
6. Zhai Y, Ghobrial RM, Busuttil RW, et al. Th1 and Th2 cytokines in organ transplantation: Paradigm lost? Crit Rev Immunol 1999; 19: 155.
7. Ganschow R, Broering DC, Nolkemper D, et al. Th2 cytokine profile in infants predisposes to improved graft acceptance after liver transplantation. Transplantation 2001; 72: 929.
8. Mottram PL, Han WR, Purcell LJ, et al. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995; 59: 559.
9. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525.
10. ZengZ,Castano AR, Segelke BW,etal. Crystal structureofmouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 1997; 277: 339.
11. Kawano T, Cui J, Koezuka Y,et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626.
12. Matsuda JL, Gapin L, Baron JL, et al. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003; 100: 8395.
13. Stetson DB, Mohrs M, Reinhardt RL, et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003; 198: 1069.
14. Godfrey DI, Kronenberg M. Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379.
15. Morecki S, Panigrahi S, Pizov G, et al. Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol 2004; 32: 630.
16. Hashimoto D, Asakura S, Miyake S, et al. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 2005; 174: 551.
17. Seino K, Yanagisawa K, Taniguchi H, et al. The effect of alpha-galactosylceramide upon allogenic rejection. Transplant Proc 2001; 33: 437.
18. Berkers CR, Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci 2005; 26: 252.
19. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531.
20. Yamamura T, Miyamoto K, Illes Z, et al. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr Top Med Chem 2004; 4: 561.
21. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
22. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192: 741.
23. Sidobre S, Kronenberg M. CD1 tetramers: A powerful tool for the analysis of glycolipid-reactive T cells. J Immunol Methods 2002; 268:107.
24. Chen YH, Chiu NM, Mandal M, et al. Impaired NK1 + T cell development and early IL-4 production in CD1-deficient mice. Immunity 1997; 6: 459.
25. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
26. Chan M, Pearson GJ. New advances in antirejection therapy. Curr Opin Cardiol 2007; 22: 117.
27. Coffman RL, Seymour BW, Lebman DA, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 1988; 102: 5.
28. Parekh VV, Singh AK, Wilson MT, et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 2004; 173: 3693.
29. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 2006; 108: 618.
30. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994; 180: 1097.
31. Seino KI, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 2001; 98: 2577.
32. Jiang X, Kojo S, Harada M, et al. Mechanism of NKT cell-mediated transplant tolerance. Am J Transplant 2007; 7: 1482.
33. Morita M, Motoki K, Akimoto K, et al. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995; 38: 2176.
34. Chen H, Qi S, Xu D, et al. The immunosuppressive effect of rapamycin on mouse small bowel transplantation. Transplantation 1996; 61: 523.
35. Jiang X, Shimaoka T, Kojo S, et al. Cutting edge: Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. JImmu-nol2005; 175: 2051.
36. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521.
37. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702.
38. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201:1503.
39. Motohashi S, Ishikawa A, Ishikawa E et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006; 12: 6079.